These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported Terminated 2012-004463-41 - Ensaio clínico prospectivo, de fase IIa, multicêntrico, sem ocultação e não controlado para avaliar a eficacia e tolerabilidade do tratamento com eribulina como agente único de primeira linha em ... 2015-12-02 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-004698-17 A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with HER2 negative, ER+ metastatic bre... 2020-01-31 bad-data
Reported results 2015-003892-31 A multicenter, international, non-controlled, phase II trial to identify the molecular mechanisms of resistance and sensitivity to palbociclib re-challenge upon progression to a palbociclib combinatio... 2020-10-27 due-trials
Completed, but no date, and reported results Terminated 2015-004828-66 A phase IIa clinical trial to evaluate the safety and efficacy of osirmertinib (AZD9291) in first-line patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer an... bad-data
Reported results 2016-001888-36 A phase II clinical trial of radium-223 activity in patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression while on abiraterone acetate or enzalutamide bes... 2021-02-28 due-trials
Other 2016-002676-27 Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study not-yet-due
Ongoing 2016-002689-30 Multicenter open-label, phase II trial, to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER2-negative breast cancer Ensayo fase II, abierto y multic... not-yet-due
Ongoing 2016-002892-80 A two-stage Simon Design phase II study for NOn-BRCA metastatic BReast cancer (MBC) patients with homologous recombination deficiency treated with OLAparib single agent (NOBROLA study) Estudio de f... not-yet-due
Ongoing 2016-004513-27 A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes Estudio de fase II de pembroliz... not-yet-due
Listed as ongoing, but also has a completion date 2017-002781-48 INTERNATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CONTINUATION OF PALBOCICLIB IN COMBINATION WITH SECOND-LINE ENDOCRINE THERAPY IN HORM... 2023-02-02 bad-data
Ongoing 2017-004323-72 Multicenter, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Niraparib plus Aromatase Inhibitors for Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 ... not-yet-due
Not reported Terminated 2017-004324-30 A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally- recurrent or metastatic breast cancer patients after progressi... 2021-03-31 due-trials
Ongoing 2018-001213-32 Effectiveness of olaparib plus trastuzumab in HER2-positive BRCA-mutated or Homologous Recombination Deficiency (HRD) advanced breast cancer patients – The OPHELIA Study – Eficacia de olaparib en c... not-yet-due
Reported results 2018-001702-28 Neoadjuvant Letrozole and Palbociclib in patients with Stage II-IIIb breast cancer, HR (+) / HER2 (-) phenotype and Intermediate (18-25) or High (>25) Recurrence-Score by Oncotype-DX; analysis of RS a... 2020-10-29 due-trials
Ongoing 2018-004648-44 A multicentre, Open-Label, Non-comparative, three-arm, phase IIa trial of Ipatasertib (GDC-0068) in Combination with non-Taxane chemotherapy agents for taxane-pretre... not-yet-due
Ongoing 2019-001172-11 A Multicenter, Open-Label, Single-ARm, PHase II Clinical Trial to Evaluate the Efficacy and Safety of INCMGA00012 in Advanced Penile SquamoUS Cell Carcinoma. ORPHEUS Phase II Study of the Efficacy of ... not-yet-due
Ongoing 2019-001503-20 PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FIRST LINE ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB (AVASTIN®) IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NEGATIVE... not-yet-due
Ongoing 2019-001739-29 A Multicenter, Open-Label, Single-Arm, Multicohort Phase II Clinical Trial of Trastuzumab Deruxtecan (DS-8201a) in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer with ... not-yet-due
Ongoing 2019-003096-20 A randomized phase II trial to evaluate the antitumor activity of Enzalutamide and Talazoparib (PF-06944076) for the treatment of metastatic hormone-naïve prostate cancer Ensayo de fase II randomiz... not-yet-due
Ongoing 2020-000397-18 A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic CArcinoma PaTIents. PECATI Studio ... not-yet-due
Ongoing 2020-001160-28 A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined with Pembrolizumab (MK-3475) in Patients with Coronavirus Disease 2019 (COVID-19)-Pneum... not-yet-due
Ongoing 2020-001648-24 A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a short course of induction chemotherapy with paclitaxel as fi... not-yet-due
Ongoing 2020-003205-66 Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2) Estrategia sin quimioterapia basada en la repuesta patol... not-yet-due
Ongoing 2022-001397-61 Multicenter, Open-label,Single arm,Phase II Clinical Trial to Improve Sacituzumab Govitecan Tolerance in Patients with Metastatic Triple-Negative Breast Cancer.–The PRIMED Study– Ensayo clínico mul... not-yet-due